NCT07404735CompletedPhase 1
A Randomized, Open-label and Parallel Study to Evaluate the Pharmacokinetics and Safety of CKD-846 in Healthy Male Subjects
Chong Kun Dang Pharmaceutical1 site in 1 country34 target enrollmentStarted: February 23, 2026Last updated:
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 34
- Locations
- 1
- Primary Endpoint
- Plasma Concentration of D091
Study Overview
Brief Summary
A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
Detailed Description
A randomized, open-label and parallel study to evaluate the pharmacokinetics and safety of CKD-846 in healthy male subjects
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to 55 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy man aged between 19 to 55 at screening
- •Weight ≥ 55kg
- •Body mass index (BMI) of 18.5 to 27.0kg/m2
- •Those who agree to contraception from the first Investigational Product(IP) dosing day till 6 months after the last dosing day and decide not to provide sperm during the participation of clinical trial
- •Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial
Exclusion Criteria
- •Those who have clinically significant disease or medical history of Hepatopathy, Renal, Neurological, Immunity, Respiratory, Endocrine, urinary, tumor or Psychical disorder
- •Those who have a history of clinically significant cardiovascular diseases such as myocardial infarction, angina pectoris, ventricular arrhythmia, heart failure, left ventricular outflow tract stenosis, stroke, and transient ischemic attack within 2 years prior to the first administration of the investigational drug
- •Those with eye diseases including genetic degenerative retinal diseases, including retinitis pigmentosa
- •Those with a past history of erection lasting more than 4 hours and priapism while taking PDE5 inhibitors such as tadalafil
- •Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery which can interfere with drug absorption
- •Persons with a history of clinically significant hypersensitivity to drugs or additives, including ingredients of clinical investigational drugs
- •Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •A person who is judged to be unsuitable as a test subject in a screening test conducted within 28 days before administration of the investigational drug
- •Those who has a drug abuse history within one year or positive reaction on urine drug screening test.
- •Those who has taken over-the-counter or prescription drugs, excluding topical agents without significant systemic absorption, within a specified period of time and the administered drug is judged to have an effect on this test or may affect the safety of the subject
- •People who need to take nitrate preparations or nitric oxide donors etc. regularly or intermittently during the clinical trial period
- •Those who continuously smoke excessively or consume caffeine or alcohol
- •A person who consumed food containing grapefruit within 7 days before the first administration of the investigational drug
- •Persons who participated in another clinical trial (including bioequivalence test) and received an investigational drug within 180days prior to the date of first administration of the investigational drug
- •Those who donated whole blood within 60 days before the first date of administration and donated ingredients within 30 days
- •Those who have received blood transfusion in 30 days
- •Those who are deemed insufficient to participate in clinical study by investigators
Arms & Interventions
R (Reference group)
Experimental
D091, Multi dose
Intervention: D091 (Drug)
A3 (Test group)
Experimental
CKD-846, Single dose
Intervention: CKD-846 (Drug)
A1 (Test group)
Experimental
CKD-846, Single dose
Intervention: CKD-846 (Drug)
A2 (Test group)
Experimental
CKD-846, Single dose
Intervention: CKD-846 (Drug)
Outcomes
Primary Outcomes
Plasma Concentration of D091
Time Frame: Pre-dose, Post-dose Day1~Day34 (During the administration period)
Concentration of During the administration period
Plasma Concentration of CKD-846
Time Frame: Pre-dose, Post-dose Day1~Day91 (During the administration period)
Concentration of During the administration period
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Study BT8009-100 in Patients with Nectin-4 Expressing Advanced Malignancies.2023-509781-37-00Bicycletx Limited254
Recruiting
Phase 2
A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not Responsive After Treatment or Who Had Myeloma Which Has Returned After a Period of Treatment2023-508727-12-00Celgene Corp.46
Completed
Phase 1
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001NCT07378579Alumis Inc52
Recruiting
Phase 1
Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentNCT07282093Ascentage Pharma Group Inc.48
Completed
Phase 1
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy VolunteersType 2 DiabetesNCT07304700Chong Kun Dang Pharmaceutical30